Top Story

FDA grants aldoxorubicin orphan drug status

October 1, 2014

CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma multiforme, small cell lung cancer and ovarian cancer.

Aldoxorubicin is a modified version of the chemotherapeutic agent doxorubicin, combined with a novel single-molecule linker that binds directly and specifically to circulating albumin. This combination allows patients to receive higher doses of doxorubicin while reducing its toxic side effects.

Meeting News Coverage

Crizotinib shows promise in ROS1-rearranged advanced NSCLC

September 27, 2014
Crizotinib induced a high response rate in patients with advanced non–small cell lung cancer who harbored ROS1 rearrangements, according to study results…
In the Journals

RET mutation identified as potential novel target in SCLC

September 25, 2014
The newly identified RET M918T somatic mutation in small cell lung cancer exhibited widely variable expression and was associated with increased cell proliferation…
figure Cover StoryPublication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and oncology research…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

FDA News

FDA grants aldoxorubicin orphan drug status

October 1, 2014
CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma…
Meeting News Coverage

Crizotinib shows promise in ROS1-rearranged advanced NSCLC

September 27, 2014
Crizotinib induced a high response rate in patients with advanced non–small cell lung cancer who harbored ROS1 rearrangements, according to…
In the Journals

RET mutation identified as potential novel target in SCLC

September 25, 2014
The newly identified RET M918T somatic mutation in small cell lung cancer exhibited widely variable expression and was associated with increased…
figure Cover Story Publication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and…
figure Editorial Publication Exclusive

I’d like to agree with you … but then we’d both be wrong!

HemOnc Today, September 25, 2014
Derek Raghavan, MD, PhD
I sometimes fear that I am a natural curmudgeon, or at the very least a true cynic.If you have read my recent editorials and op-eds, it may seem I…
In the Journals

Lung cancer screening of Medicare-eligible patients associated with greater benefits, risks

September 24, 2014
Screen-detected lung cancer prevalence, as well false-positive results, were higher among Medicare-eligible participants compared with younger…
figure In the Journals

Lung cancer diagnostic test loses specificity in areas with endemic lung infections

September 23, 2014
PET imaging with fludeoxyglucose F 18 less reliably diagnosed malignant lung lesions in populations with endemic infectious lung disease, according…
In the Journals

E-cigarettes emitted fewer carcinogenic particulates, higher toxic metals

September 19, 2014
Secondhand smoke from electronic cigarettes contained significantly fewer organic carcinogen emissions than tobacco-containing cigarettes, according…
figure

Report: Commitment to NIH, NCI funding only 'viable path' for continued success in cancer research

September 16, 2014
The scientific community’s continued quest to prevent and cure cancer has reached a crossroads, according to a report released today by the…
Industry News

NSCLC treatment market estimated to exceed $7.9 billion by 2020

September 14, 2014
The global market value of non-small cell lung cancer treatment will increase from $5.1 billion in 2013 to more than $7.9 billion by 2020 with a…
More Headlines »